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1. Introduction 
Although approximately 10% of atrial fibrillation (AF) patients have no evident cardiac 
disorder (so-called “lone” AF), the arrhythmia usually occurs in patients with structural 
heart disease. Hypertension, coronary heart disease, valvular heart disease, dilated 
cardiomyopathy, and heart failure are the most frequent cardiovascular comorbidities 
associated with AF, but this arrhythmia is frequently found also in diabetic patients, with 
prevalence rates estimated to be at least double than among patients without diabetes (1). 
Comorbidities may induce atrial fibrosis and  loss of myocardial tissue which have an 
apparent clear impact in facilitating AF by reducing the conduction velocity and possibly 
creating areas of conduction block. Fibrosis may be either a substrate for AF or a result of 
fibrillating atria and part of the so-called structural remodeling. Since atrial enlargement is 
often present in AF patients with or without comorbidities, it is difficult to establish if it 
represents the cause or the consequence of the arrhythmia. AF affects one in 25 adults aged 
60 or over and nearly one in 10 adults aged 80 or over. Due to symptoms and the increased 
risk of ischemic stroke and death in elderly patients, AF is a source of considerable concern, 
and its impact is likely to increase as the number of individuals affected by AF rises nearly 
2.5-fold during the next 50 years. The economic repercussions on national health systems 
around the world will be considerable. Like AF, diabetes mellitus is a global health problem 
with an estimated worldwide prevalence of 2.8% in 2000, which will increase to 4.4% in 2030 
(2). At least 10.3 million Americans carry a diagnosis of diabetes mellitus. Another 5.4 
million of people are estimated to have undiagnosed diabetes. Approximately 90% of 
patients with diabetes have the type 2 variety. The onset of type 2 diabetes usually precedes 
clinical diagnosis by several years. As a result, an increasing prevalence of type 2 diabetes 
cannot be divorced from the rising prevalence of atrial fibrillation in our society. Diabetic 
patients have at least twice the risk of vascular complications and cardiovascular death, 
compared with those without diabetes(3,4). Several epidemiological and pathological data 
have reported that diabetes is an independent predictor of cardiovascular disease (CVD) in 
both men and women. CVDs are considered as the cause of death in 65% of people with 
diabetes. To make matters worse, when patients with diabetes develop clinical CVD, they 
sustain a worse prognosis for survival than do CVD patients without diabetes. These 
observations suggest that it is imperative to promote coordinated efforts on behalf of 
cardiologistis, electrophysiologistis, neurologists, and primary-care providers to meet the 
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increasing challenge of stroke and death prevention and rhythm management in the 
growing population of patients with atrial fibrillation and diabetes. Since among patients 
with AF type 2 diabetes is frequently associated with cardiovascular comorbidities 
including coronary artery disease, heart failure and hypertension (AF has been observed 
three times higher in patients with hypertension)(5) it is very difficult to evaluate its 
independent predictive value for arrhythmia progression, thromboembolic and cardiac 
adverse events including death (6,7). To assess whether diabetes further increases the 
already high risk among patients with AF and concomitant cardiovascular diseases, a 
prospective large number of patients with a long-term follow-up is required. We report here 
our long-term experience in a large and selected population of patients with paroxysmal AF 
in order to identify predictors of outcome, including AF progression, ischemic stroke and 
cardiovascular death.  
2. Study population 
Patients with history of documented paroxysmal AF with at least 2 or more episodes of 
symptomatic or asymptomatic AF lasting >1 hour were recruited for this 4-year prospective 
follow-up study. Exclusion and inclusion criteria are reported in Table 1. Patients with 
arrhythmia due to potentially reversible causes such as acute or recent (<6 months) 
myocardial infarction, recent cardiac surgery, New York Heart Association class III-IV heart 
failure, severe valvular heart disease requiring surgery, uncontrolled hypertension, acute 
pulmonary disease, WPW syndrome, a history of long-QT syndrome, Brugada syndrome, 
pericarditis, substance abuse, electrolyte imbalance, hyper or hypothyroidism were 
excluded. Patients with hepatic diseases, history of thromboembolism including stroke or 
TIA, contraindication to anticoagulation therapy, or any condition that would make survival 
for 1 year unlikely were also excluded. Patients scheduled to undergo catheter ablation or 
implantation of a pacemaker or defibrillator were also excluded. All participants had to 
have been on stable therapy for AF and any underlying cardiovascular disorders for at least 
1 month before enrollment. Patients were allowed to continue all previously prescribed 
treatments for these conditions (including antiarrhythmic drugs, amiodarone, beta-blockers, 
and ACE inhibitors). 
2.1 Follow-up 
Serial control visits with ECG, 48-h Holter, echocardiography, and laboratory testing were 
scheduled at 1, 3, 6 months and thereafter once annually for 4 years. If a recurrence of AF 
was detected, the patient was asked to come in for an office visit to confirm the findings. 
Baseline evaluation included a past medical history of cardiovascular and endocrine 
disorders as well as a history of precipitating events. A complete blood count, urinalysis, 
thyroid-function tests, hepatic panel, lipid profile, and serum chemical measurements were 
obtained at baseline and at each control visit thereafter. Transesophageal echocardiography 
was performed at baseline to rule out atrial thrombi and annually. Recurrent episodes were 
pharmacologically managed by conventional ADT (propafenone, flecainide, and/or sotalol 
as first-line drugs in patients without structural heart disease or amiodarone as a single 
drug or in combination in patients with structural heart disease or in case of first-line drugs 
failure) according to AF management guidelines (8,9). Electrical cardioversion was 
performed if necessary or in patients with persistent AF refractory to ADT. Antithrombotic 
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therapy with warfarin (INR between 2.0 and 3.0) was initially applied after stroke risk 
assessment according to the current AF guidelines recommendations (8,9). Patients with 
comorbidities or those with at least one moderate risk factor for thromboembolism 
regardless of AF clinical form were prescribed warfarin. Electrical cardioversion was 
performed for a maximum of 3 attempts.  Patients with recurrent AF were followed monthly 
in an outpatient setting. The outcomes evaluated in this analysis were arrhythmia 
progression, cardiovascular mortality and major thromboembolic events. 
 
Inclusion criteria: 
Age between 18 and 85 
 
Exclusion criteria: 
Left ventricular ejection fraction <30%  
NYHA functional class III-IV  
Left atrial size >60mm 
AF burden > 2 episodes/month 
Uncorrected severe valvular heart disease 
Contraindication to anticoagulation 
Presence of left atrial thrombus 
Patients scheduled to undergo catheter ablation or implantation of a pacemaker or 
defibrillator 
Prior attempt at catheter or surgical ablation for atrial fibrillation 
Recent (6 months) history of myocardial infarction 
Cardiac surgery for congenital, valvular, aortic or coronary heart disease 
History of cerebrovascular accidents  
Pregnancy 
Life expectancy less than 1 year 
Significant comorbidities: cancer, end stage renal disease, severe obstructive lung disease, 
cirrhosis, etc 
Inability or unwillingness to provide written informed consent  
Table 1. Inclusion and Exclusion Criteria 
2.2 Definitions 
Paroxysmal AF was defined as recurrent AF that was self-terminating within 7 days. 
Persistent AF is defined as AF that was sustained beyond 7 days, or lasting less than 7 days 
but requiring pharmacologic or electrical cardioversion for termination. Ischemic stroke was 
defined as neurological deficit of sudden onset lasting >24 hours and caused by ischemia. 
Cardiovascular (CV) death was defined as death due to cardiovascular causes (myocardial 
infarction or heart failure).  
3. Results 
3.1 Study population 
Among 5210 screened patients with paroxysmal AF, 1931 (mean age, 61.5 years, M, 47.2%) 
fulfilled inclusion and exclusion criteria and completed a 4-year follow-up period. Baseline 
clinical characteristics of the study population are shown in Table 1. Many patients had a 
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history of hypertension with hypetensive heart disease (44.8%)  or coronary artery disease 
(31.6%). A total of 9.5% of patients had recent heart failure and 8.8% had valvular heart 
disease often with mitral valve disease. Type 2 diabetes mellitus was present in 13.9% of 
patients and in many of them (85 patients) diabetes was of long duration (median duration 
15 years) and poor controlled with oral antidiabetic therapy as assessed by glycosylated 
hemoglobin (median 8%)). AF burden was 2.05±0.2 (episodes/month). At the time of 
enrollment, 35% of the patients were receiving amiodarone alone or in combination, 25.2% 
were receiving beta-blockers or sotalol, 20% were receiving ACE inhibitors, and only 20% of 
them were receiving chronic anticoagulant therapy with warfarin. Class I antiarrhythmic 
agents were prescribed in 30% of patients. Adverse drug reactions occurred in 115 patients 
during class I antiarrhythmic drugs (75 patients), amiodarone alone (30 patients) or in 
combination (10 patients). No serious complications developed and long-term 
antiarrhythmic drug therapy was not permanently discontinued in any patient. 
3.2 Atrial fibrillation progression  
At 4 years, 1452 patients had had at least a recurrence of AF , 183 patients remained in stable 
sinus rhythm on antiarrhythic drug therapy and the remaining 276 patients had progressed 
to persistent AF despite conventional ADT alone or in combination. Intensive Holter 
recordings revealed that in 68/183 patients, of whom 50 with diabetes mellitus, AF 
progression was silent. The baseline characteristics of patients with and without AF 
progression were compared for demographics at study entry (Table 2). Patients who 
progressed were older and had more comorbidities including type 2 diabetes and higher 
baseline AF burden than those who did not. On the baseline echocardiogram, patients with 
AF progression had larger left atrial diameters. The median interval between the onset of 
recurrent paroxysmal and persistent AF was 33.5 months (range 5-38). Patients who 
progressed received more frequently drugs associated with heart failure (ACE inhibitors 
and/or diuretics) and many of them had oral anticoagultion therapy with warfarin. 
Electrical cardioversion was more frequently used before and after progression but the 
arrhythmia recurred 32±18 days after electrical cardioversion requiring multiple 
hospitalizations.  
3.3 Complications 
Cardiovascular events. During a median follow-up of 35 months, 84 patients died due to 
cardiovascular causes (Table 2) with a cumulative 4-year cardiovascular mortality rate of 4.3%. 
All patients were older than 65 years of age and all had comorbidities including heart failure, 
diabetes, coronary artery disease and hypertensive cardiomyopathy alone or in combination. 
Arrhythmia progression occurred in 49/84 (58.3%) before death which was commonly due to 
worsening of heart failure or acute heart failure (55 patients)  secondary to inadequate control 
of the ventricular rate at the time of recurrent episodes of persistent arrhythmia at rapid 
ventricular rate (115 ±15 bpm) or hypertensive crises with pulmonary edema (29 patients). All 
patients at the time of death were on amiodarone therapy and warfarin. Thromboembolic events. 
During a median follow-up of  25 months, thromboembolism developed in 140 patients (Table 
2) with a 4-year cumulative stroke rate of 7.3%. Arrhythmia progression occurred in 58/140 
(41.4%) before thromboembolic events. All patients at the time of thromboembolism were on 
warfarin but subtherapeutic doses were found in many of them (40%). 
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Male sex, n (%) 911(47.2) 1095(66.1) 165 (59.7) 0.024 
Age, (years) 61.5±7.4 61.2±7.4 62.4±7.2 0.021 
Hypertension, n (%) 865 (44.8) 718 (43.8) 147 (53.2) 0.001 
Heart Failure, n (%) 184 (9.5) 119 (7.1) 65 (23.5) <0.001 
Diabetes mellitus, n (%) 270 (13.9) 188 (11.3) 82 (29.7) <0.001 
Valvular disease, n (%) 171 (8.8) 141 (8.5) 35 (12.6) 0.020 
Coronary artery disease 611 (31.6) 514 (31) 93 (33.6) 0.382 
LA diameter, (mm) 42±3.3 41.5±3.2 42.8±3.4 <0.001 
LV EF, (%) 54±5.3 54±5.0 51±6.5 <0.001 
AF burden, 
(episodes/month) 
2.2 ±0.5 2.2±0.4 2.4 ±0.7 <0.001 
AF duration, (months) 50.4±7.3 53±3.5 58±4.6 <0.001 
Thromboembolism, n (%) 140 (7.2) 82 (4.9) 58 (21) <0.001 
CV Death, n (%) 84 (4.3) 36 (2.1) 48 (17.3) <0.001 
Table 2. Baseline characteristics of patients with paroxysmal AF 
3.4 Risk factors of progression, thromboembolic events and death 
Multivariate analysis demonstrated that many comorbidities including diabetes mellitus, 
heart failure, and coronary artery disease were common predictors of arrhythmia 
progression as well as of thromboembolic events and death (Tables 3-5). In addition, low 
ejection fraction, left atrial enlargment, female gender, and older age also predicted all 
adverse events. AF burden was a strong predictor of arrhythmia progression but did not 
predict thromboembolic events/death.  Diabetes and heart failure were the strongest 





p-value Adjusted HR 95% CI 
AF burden 0.545 <0.001 1.724 1.449 2.051 
Ejection fraction -0.070 <0.001 0.933 0.912 0.954 
Sex 0.335 0.031 1.398 1.032 1.894 
Age 0.043 0.001 1.044 1.018 1.070 
Coronary artery disease 0.328 0.015 1.388 1.067 1.806 
Heart failure 0.674 <0.001 1.963 1.412 2.728 
Diabetes mellitus 0.568 <0.001 1.765 1.301 2.396 
Left atrial diameter 0.050 0.007 1.051 1.013 1.090 
Valvular disease 0.537 0.004 1.712 1.191 2.460 
Table 3. Multivariate Cox analysis for AF progression 
4. Discussion  
This is the largest prospective long-term study which provides additional data on predictors 
of arrhythmia progression and prognosis among a selected population with paroxysmal AF 
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which represents the vast majority of patients with paroxysmal AF commonly seen in 
clinical practice. The long-term results while confirming the role of associated comorbidities 
to predict AF progression, clearly demonstrate that type 2 diabetes is one of the strongest 
predictor of both arrhythmia progression and prognosis.  AF burden of at least 2 
episodes/month was a strong predictor of arrhythmia progression but this arrhythmia 
burden, unlike diabetes and cardiovascular comorbidities did not predict stroke and death. 
AF progression was discrete and at 4 years occurred only in a minority of patients (14.3%), 









Ejection fraction -0.043 0.005 0.958 0.930 0.987 
Sex 0.696 0.004 2.005 1.256 3.202 
Age 0.120 <0.001 1.128 1.082 1.176 
Coronary artery disease 1.345 <0.001 3.839 2.207 6.678 
Heart failure 1.407 <0.001 4.085 2.533 6.587 
Diabetes mellitus 1.705 <0.001 5.500 3.208 9.431 
Left atrial diameter 0.102 <0.001 1.108 1.056 1.162 









Ejection fraction -0.066 <0.001 0.936 0.904 0.970 
Sex 1.576 <0.001 4.836 2.017 11.594 
Age 0.057 0.054 1.059 0.999 1.121 
Coronary artery disease 0.741 0.051 2.097 0.996 4.417 
Heart failure 2.557 <0.001 12.891 4.977 33.387 
Diabetes mellitus 1.628 <0.001 5,092 2,233 11.615 
Left atrial diameter 0.059 0.065 1.061 0.996 1.130 
Table 5. Multivariate Cox analysis for cardiovascular death 
4.1 Predictors of AF progression, ischemic stroke and death 
Risk factors for the transition from paroxysmal to persistent forms of AF may be similar to 
those predisponing to incident AF, but there are very limited data on their identification for 
secondary prevention in order to reduce arrhythmia progression and associated 
complications such as thromboembolic events or death. Patients with AF have a substantial 
risk of stroke, which is modified by the presence or absence of several risk factors. These risk 
factors have been used to develop thromboembolic risk stratification schemes, which have 
arbitrarily divided the risk into low, intermediate, and high risk strata. Multivariate pooled 
analysis demonstrated that cardiovascular comorbidities and diabetes were independently 
predictive of arrhythmia progression as well as of stroke and CV death while baseline AF 
burden of 2 episodes/month was a strong predictor of arrhythmia progression, but at 4 
years was not sufficient to predict serious adverse events and death. Our data also 
demonstrate that advancing age, female gender and the presence of coronary artery disease 
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are independently predictive of adverse events including death. These findings suggest that 
in patients with paroxysmal AF thromboembolic risk stratification schemes using these risk 
factors are useful. Therefore, potential additional risk factors listed in the 2006 
ACC/AHA/ESC guidelines (8) as “less validated or weaker risk factors” including female 
gender, age 65-74  years, and coronary artery disease should be instead considered as 
independent strong risk factors. Many of these variables have been expressed in the 
CHA2DS2-VASc (Congestive heart failure, Hypertension, Age>75 years, Diabetes mellitus, 
previous Stroke/transient ischemic attack, Vascular disease, Age 65-74 years, Sex category,) 
score, which has been proposed to complement the CHADS2 score. 
4.2 Silent progression of AF  
In the present study, AF progression from paroxysmal to persistent AF was silent in many 
patients as documented by the intensive Holter monitoring. Of note, about a half of patients 
with AF progression had diabetes mellitus. These findings are important in terms of 
pathophysiology and therapy suggesting that oral anticoagulation therapy with warfarin in 
patients at high risk should be frequently and constantly monitored to avoid subtherapeutic 
intensity (INR below 2.0) regardless of the presence of symptoms. In the absence of an 
accurate arrhythmia monitoring by intermittent ECG recordings, asymptomatic transition to 
more persistent forms, particularly in diabetic patients, may be undetected increasing the 
risk of theromboembolic and cardiovascular complications.  
4.3 Comparison with previous studies 
The results of the present study extend the results of previous studies on AF progression 
from paroxysmal to persistent AF (10-14). In the CARAF (Canadian Registry of Atrial 
Fibrillation Study) study,  underlying heart disease and age were reported as independent 
factors of AF progression (10). Nieuwlaat et al reported univariate analysis of AF 
progression in the Euro Heart Survey (EHS), but independent risk factors were not analyzed 
(11). De Vos et al (12) have recently reported interesting data on the clinical correlates of AF 
progression and prognosis in the patients enrolled in the Euro Heart Survey of AF (13). In 
agreement with our data but during a much shorter follow-up period (only 1 year), 
progression to persistent AF occurred in 15% of Euro Heart Survey patients. Based on these 
data, the Authors have suggested a new risk stratification score (HATCH) to identify 
patients prone to arrhythmia progression. Recently, we have reported AF progression in 106 
patients with first of whom 52 with comorbidities AF and diabetes was a strong predictor of 
arrhythmia progression (14). The present study reports additional data among a large 
patient population with paroxysmal AF. A predefined baseline AF burden before 
enrollment was purposively included to enhance the clinical applicability of the results and, 
unlike the study by de Vos et al (12), patients with AF who required pharmacological 
cardioversion for restoration of sinus rhythm were considered as persistent AF patients and 
then  were excluded. The results at 4 years while confirming the independent role of many 
cardiovascular comorbidities as predictors of AF progression, for the first time show type 2 
diabetes mellitus as a strong independent predictor of AF progression, thromboembolism 
and cardiovascular death. In the analysis of de Vos and colleagues (12), diabetes also 
occurred more frequently in patients who progressed as compared with those who did not 
(19% vs 14%), but no significant differences were found and this may be due to several 
reasons including a shorter follow-up, misclassification of paroxysmal AF in many patients 
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and a less accurate rhythm monitoring. Analysis of AF progression and predictors of 
prognosis requires a well defined AF burden prior to enrollment which should not be based 
on the patients’reported history alone as it may be unreliable. Previous trials frequently 
have been based exclusively on electrocardiography performed at scheduled visits or on the 
patient’s report of symptoms which may explain why different rates of progression and 
predictors have been reported. Recently, the results of the ADVANCE study suggested that 
AF in diabetic patients should be regarded as a marker of adverse outcome and prompt 
aggressive management of all risk factors (15). Although it seems to be conceivable that 
many comorbidities including type 2 diabetes should be independent predictors of stroke 
and mortality in patients with nonvalvular atrial fibrillation, available data do not provide 
strong support. The results of the present study demonstrate that type 2 diabetes as well as 
cardiovascular comorbidities are independently predictors of thromboembolism and 
cardiovascular death.  We believe that patients with paroxysmal AF without prior stroke 
with at least one risk factor such as advancing age, underlying heart or metabolic disease 
and a well defined baseline arrhythmia burden, as those enrolled in the present study,  
indeed represent the vast majority of patients with AF commonly seen in real life clinical 
practice. Large clinical studies require years for completion, but they are required to 
determine the impact of several risk factors on mortality and other long-term outcomes. In 
our experience, older patients, particularly females with cardiovascular comorbidity and 
diabetes mellitus are at highest risk of adverse outcomes and require chronic 
anticoagulation therapy with warfarin.   
5. Conclusions 
Our experience provides new evidence on characteristics and outcome among a large cohort 
of selected patients with paroxysmal AF with a minimal use of anticoagulation treatment. 
These data, while confirming the role of many cardiovascular comorbidities in predicting 
adverse outcomes, demonstrate that diabetes mellitus is an independent strong predictor of 
AF progression, stroke and CV death. AF progression in diabetics may be frequently silent 
which may result in higher risk of adverse outcome. 
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